Eli Lilly Pays $960M For Migraine Treatment Developer
Pharmaceutical giant Eli Lilly and Co. has agreed to buy migraine treatment developer CoLucid Pharmaceuticals Inc. for roughly $960 million, the companies said Wednesday, in a deal guided by legal advisers...To view the full article, register now.
Already a subscriber? Click here to view full article